Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

BACKGROUND: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48 to continuing three-drug daily oral current antiretroviral therapy (CAR). Resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Swindells, Susan, Lutz, Thomas, Van Zyl, Lelanie, Porteiro, Norma, Stoll, Matthias, Mitha, Essack, Shon, Alyssa, Benn, Paul, Huang, Jenny O., Harrington, Conn M., Hove, Kai, Ford, Susan L., Talarico, Christine L., Chounta, Vasiliki, Crauwels, Herta, Van Solingen-Ristea, Rodica, Vanveggel, Simon, Margolis, David A., Smith, Kimberly Y., Vandermeulen, Kati, Spreen, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711605/
https://www.ncbi.nlm.nih.gov/pubmed/34261093
http://dx.doi.org/10.1097/QAD.0000000000003025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711605/
https://www.ncbi.nlm.nih.gov/pubmed/34261093
http://dx.doi.org/10.1097/QAD.0000000000003025

Ejemplares similares